Stocktoria
ANI PHARMACEUTICALS INC ANIP
ANI PHARMACEUTICALS INC (ANIP) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.06% (safety: safe). FY2025 revenue was $883.4M at a 8.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.33 |
| Retained earnings / assets | -0.016 |
| EBIT / assets | 0.077 |
| Equity / liabilities | 0.601 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ANIP | ANI PHARMACEUTICALS INC | 6/9 | 3.26 | 24.5 | +43.8% |
| HRMY | Harmony Biosciences Holdings, Inc. | 5/9 | 7.17 | 12.9 | +21.5% |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
| IONS | IONIS PHARMACEUTICALS INC | 3/9 | 1.12 | — | +33.8% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
About ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
FAQ
Is ANIP financially healthy?
ANI PHARMACEUTICALS INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ANIP pay a dividend, and is it safe?
Yes. ANI PHARMACEUTICALS INC pays a dividend yielding about 0.06% with a 1.5% payout ratio, rated “safe” for safety.
How profitable is ANIP?
In FY2025, ANI PHARMACEUTICALS INC had a net margin of 8.9% and a return on equity of 14.5%.
Is ANIP overvalued or undervalued?
ANI PHARMACEUTICALS INC trades at about 22.6× trailing earnings — below its 10-year norm (10-year range 21.6×–177.8×, median 41.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ANIP?
The average Wall-Street price target for ANI PHARMACEUTICALS INC is $112.71, about 50.1% above the recent price, from 7 analysts.
Is ANIP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ANI PHARMACEUTICALS INC: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 24.5×, a dividend yield of 0.06%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.